Major Western device and medical technology firms launched Asia Pacific Medical Technology Association, or APACMed, pledging the association would unite a fragmented effort to work with regulators across a region that is both lucrative and frustrating on issues ranging from import rules to public tender guidelines.
J&J's Janssen unit is recalling one lot of Ortho-Cept contraceptive tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
Johnson & Johnson has extended its tendrils into another biotech incubator. Having played a role in the formation of incubators in the U.S., Canada and Israel in recent years, the Big Pharma has now lent its support to an initiative to foster the development of Scottish life science startups.
Johnson & Johnson's diabetes care business experienced a year-over-year revenue decline of 2.2% in 2015 and fell 8.7% for the year. But J&J executives are optimistic about a turnaround, citing the recent launch of the drug-delivering Animas Vibe continuous glucose monitor and insulin pump, and longer term plans for a wearable insulin pump.
In a study, Janssen Pharmaceuticals' once-a-month injectable for schizophrenia resulted in better outcomes than daily oral competitors, as measured by real-world (as opposed to strictly clinical) outcomes like arrest or psychiatric hospitalization.
The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to PMLiVE based on sales info from GlobalData.
Johnson & Johnson's SGLT2 inhibitor Invokana (canagliflozin)--among a handful of drugs in the new category of DPP-4 drugs for diabetes--not only took a big jump in sales for the first quarter but also made some significant market-share gains.
San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.
IBM increased its presence in the device world in a major way, announcing a collaboration around famous supercomputer Watson with Medtronic, Johnson & Johnson and Apple.